- Conditions
- Vulvovaginal Candidiasis
- Interventions
- NDV-3A, NDV-3, Placebo
- Biological
- Lead sponsor
- NovaDigm Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
- Interventions
- Ibrexafungerp
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
- Conditions
- Vulvovaginal Candidiasis
- Interventions
- MGCD290
- Drug
- Lead sponsor
- MethylGene Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
- Conditions
- Vulvovaginitis, Vaginitis
- Interventions
- clindamycin phosphate/butoconazole nitrate, clindamycin phosphate, butoconazole nitrate
- Drug
- Lead sponsor
- Lumara Health, Inc.
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 1,443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Enterprise, Alabama • Chandler, Arizona + 69 more
- Conditions
- Candida Vulvovaginitis
- Interventions
- Fluconazole, SCY-078
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more
- Conditions
- Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Interventions
- Oral Encochleated Amphotericin B (CAMB), Fluconazole
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
- Interventions
- Boric acid, Placebo
- Drug · Other
- Lead sponsor
- pH-D Feminine Health LLC
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161), Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Bacterial Vaginosis, Candidiasis, Trichomoniasis
- Interventions
- Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
- Interventions
- vaginal cooling device
- Device
- Lead sponsor
- Coologics, Inc
- Industry
- Eligibility
- 22 Years to 49 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
- Conditions
- Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
- Interventions
- Xpert® Xpress MVP test, Usual Care
- Diagnostic Test
- Lead sponsor
- Sharon L Hillier
- Other
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
- Interventions
- Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture
- Diagnostic Test
- Lead sponsor
- Nanopath, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Bacterial Vaginosis, Vulvovaginal Candidiasis
- Interventions
- Phexxi
- Drug
- Lead sponsor
- Queen's Medical Center
- Other
- Eligibility
- 18 Years to 54 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Interventions
- Oral Encochleated Amphotericin B (CAMB)
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Vaginitis, Vulvar Diseases
- Interventions
- Vaginitis panel
- Diagnostic Test
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
- Conditions
- Candida Vulvovaginitis
- Interventions
- Ibrexafungerp, Placebo
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
- Conditions
- Bacterial Vaginosis, Vulvovaginal Candidiasis
- Interventions
- TOL-463
- Drug
- Lead sponsor
- Toltec Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Seattle, Washington
- Conditions
- Vaginitis
- Interventions
- Terazol or oral fluconazole for candidal vaginitis, Metronidazole or Clindamycin for Bacterial Vaginosis, Flagyl for definitively diagnosed vaginal trichomoniasis, Empiric Management
- Drug · Other
- Lead sponsor
- Agency for Healthcare Research and Quality (AHRQ)
- Federal
- Eligibility
- 18 Years to 52 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161), Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
- Conditions
- Candida Vulvovaginitis
- Interventions
- Ibrexafungerp, Placebo
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 21
- States / cities
- Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
- Conditions
- Vaginal Infection
- Interventions
- TOL-463 Vaginal ovule, TOL-463 Vaginal gel
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Health, Vulvovaginal Candidiasis
- Interventions
- Miconazole nitrate, Magnetic resonance imaging, Moderate levels of exercise
- Drug · Procedure · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Interventions
- Ibrexafungerp
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Rogers, Arkansas